click below
click below
Normal Size Small Size show me how
Diabetes
| Question | Answer |
|---|---|
| Type 1 Diabetes | results from an autoimmune destruction of the pancreatic B cells. Usually develops in persons younger than 30 years of age |
| Type 2 diabetes | development is attributed to a much more sedentary lifestyle and lack of exercise. Usually develops in persons older than 40 years, however more and more cases are being reported for those under 20 years old |
| Hyperglycemia | refers to an abnormally high level of glucose (sugar) in the blood |
| Hypoglycemia | condition characterized by abnormally low levels of glucose (sugar) in the blood |
| Hyperkalemia | medical condition characterized by elevated levels of potassium (an essential electrolyte) in the blood. |
| Glycosuria | the presence of glucose (sugar) in the urine |
| Prophylactic | refers to measures or treatments designed to prevent disease or a condition before it occurs |
| UTI | Urinary Tract Infection |
| Xerostomia | medical term for dry mouth |
| Arthralgia | Joint pain |
| Macroangiopathy | refers to damage or disease affecting the large blood vessels |
| Microangiopathy | refers to damage or disease affecting the small blood vessels |
| Ketoacidosis | serious condition characterized by the buildup of acids called ketones in the body, which occurs when the body breaks down fat for fuel instead of carbohydrates. This can lead to a dangerously high level of acidity in the blood |
| Insulins | insulin aspart (NovoLog) rapid-acting, insulin lispro (Humalog) rapid-acting, insulin regular (Humulin R) short-acting, insulin glargine (Lantus) long-acting |
| Biguanides | metformin (Glucophage) |
| SGLT-2 Inhibitors | canagliflozin (Invokana) |
| GLP-1 Receptor Agonists | liraglutide (Victoza), semaglutide (Ozempic) |
| Sulfonylureas | glimepiride (Amaryl), glipizide (Glucotrol), glyburide (DiaBeta) |
| DPP-4 Inhibitors | sitagliptin (Januvia) |
| Thiazolidinediones | pioglitazone (Actos) |
| two primary pancreatic hormones | Insulin: Promotes fuel storage, Glucagon: Promotes fuel mobilization |
| A1C | Is a blood test that measures the average level of blood glucose (sugar) over the past two to three months, It reflects how well blood sugar levels have been controlled over a period of time, an indication of long-term glucose management |
| hyperglycemia | high blood sugar |
| hyptoglycemia | low blood sugar |
| Insulin | Facilitates the uptake of glucose by cells, reducing blood sugar levels |
| Biguanides (e.g., Metformin) | Decrease glucose production in the liver and improve insulin sensitivity |
| Sulfonylureas (e.g., Glipizide) | Stimulate the pancreas to release more insulin |
| Thiazolidinediones (e.g., Pioglitazone) | Enhance insulin sensitivity in muscle and fat tissues |
| DPP-4 Inhibitors (e.g., Sitagliptin) | Increase insulin release and decrease glucagon levels in response to meals |
| GLP-1 Receptor Agonists (e.g., Liraglutide) | Mimic the effects of the hormone GLP-1 to stimulate insulin secretion, inhibit glucagon release, and slow gastric emptying |
| SGLT2 Inhibitors (e.g., Canagliflozin) | Prevent the reabsorption of glucose by the kidneys, leading to glucose excretion in urine |
| Alpha-Glucosidase Inhibitors (e.g., Acarbose) | Delay the digestion and absorption of carbohydrates in the intestines, reducing postprandial blood sugar spikes |
| Macroangiopathy | damage or disease affecting large blood vessels |
| Microangiopathy | damage or disease affecting the small blood vessels |
| Hyperlipidemia | elevated levels of lipids (fats) in the blood |
| Atherosclerosis | buildup of fatty deposits, called plaques, on the inner walls of arteries |
| Retinopathy | DM affects the blood supply to the retina Diabetes is the major cause of blindness in adults |
| Neuropathy | DM leads to the reduction in and sometimes absence of, feeling, especially in the lower extremities. |